Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic reports IN.PACT Admiral drug-coated balloon study data

Medtronic reports IN.PACT Admiral drug-coated balloon study data

19th October 2015

Medtronic has announced new clinical data showing the efficacy of its IN.PACT Admiral drug-coated balloon in the treatment of peripheral arterial disease.

Two-year clinical data from the pivotal IN.PACT SFA Trial revealed that the balloon provided superior clinical outcomes at two years compared to standard balloon angioplasty for the interventional treatment of peripheral arterial disease in the upper leg.

This comes after one-year results from the trial indicated that IN.PACT Admiral offered the highest rate of primary patency and the lowest rate of clinically-driven target lesion revascularisation at 12 months out of a number of interventional treatments.

The findings demonstrate the drug-coated balloon's superior safety and efficacy compared to standard balloon angioplasty and the sustained, longer-term clinical benefits it offers.

Brian Verrier, vice-president and general manager of Medtronic's peripheral franchise, said: "The IN.PACT Admiral DCB's cadence of strong clinical data not only demonstrates the therapy's sustained durability, but also our deep-rooted commitment to providing innovative technologies that advance healthcare together in partnership with clinicians worldwide."

This comes after the firm's new drug-filled stent recently demonstrated promising results following its initial round of implantations in patients.ADNFCR-8000103-ID-801803472-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips and straight to your inbox.